H.C. Wainwright lowered the firm’s price target on Adicet Bio (ACET) to $27 from $50 and keeps a Buy rating on the shares following the Q4 report. The firm cites the company’s higher long-term operating expenses for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Clinical Trial Uncertainty Puts Adicet Bio’s Prula-cel Program and Financial Outlook at Risk
- Adicet Bio price target lowered to $100 from $128 at Guggenheim
- Adicet Bio files $250M mixed securities shelf
- Adicet Bio reports Q4 EPS ($2.94), consensus ($2.99)
- ACET Earnings Report this Week: Is It a Buy, Ahead of Earnings?